Novavax Inc (ASX:NVAX)
4.72 AUD
-0.110 2.277%Previous Close (in AUD) | 4.83 |
---|---|
Change | -0.110 2.277% |
52 W H/L (in AUD) | 13.700/4.850 |
EBITDA (in AUD) | -574.869M |
PE Ratio | -- |
Volume | 3889695 |
Diluted Eps TTM | -6.23 |
Total Assets (in AUD) | 2258.679M |
---|---|
Total Liabilities (in AUD) | 2892.757M |
Revenue TTM (in AUD) | 1049.762M |
Cash (in AUD) | 1336.883M |
Market Cap (in AUD) | 601.077 M |
Revenue Per Share TTM | 11.697 |
Gross Profit TTM (in AUD) | -156.045M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Novavax Inc
Employees: 1992
Key Executives
Sr. No. | Name | Title | Year Born |
---|---|---|---|
1. | Mr. Stanley Charles Erck | Pres, CEO & Director | 1948 |
2. | Mr. James Patrick Kelly C.F.A. | Exec. VP, CFO & Treasurer | 1966 |
3. | Mr. John A. Herrmann III | Exec. VP, Chief Legal Officer & Corp. Sec. | 1966 |
4. | Mr. John Joseph Trizzino B.S., M.B.A. | Exec. VP and Chief Bus. & Commercial Officer | 1960 |
5. | Dr. Gregory M. Glenn | Pres of R&D | 1954 |
6. | Mr. Richard P. Crowley | Exec. VP & COO | 1957 |
7. | Dr. Gale E. Smith | Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist | 1950 |
8. | Mr. Biegie Lee | Sr. VP & Chief Information Officer | NA |
9. | Mr. Troy Morgan Esq., J.D. | Sr. VP & Chief Compliance Officer | 1971 |
10. | Ms. Erika S. Trahan | Associate Director of Investor & PR | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
NVO
Novo Nordisk A/S |
-0.530 0.407% | 129 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
NONOF
Novo Nordisk A/S |
-1.530 1.168% | 125 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
VRTX
Vertex Pharmaceuticals Inc |
+3.600 0.874% | 415.61 | 30.400 | 24.753 | 10.683 | 6.245 | 9.523 | 20.364 |
CSLLY
CSL Ltd |
-1.310 1.424% | 91 | 42.450 | 26.954 | 7.054 | 5.797 | 7.851 | 26.506 |
Income Statement
(Currency in AUD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Income Before Tax | -653.647M | -1714.536M | -418.259M | -132.694M | -184.748M |
Minority Interest | - | - | - | - | - |
Net Income | -657.939M | -1743.751M | -427.505M | -130.102M | -184.748M |
Selling General Administrative | 488.691M | 298.358M | 145.29M | 34.417M | 34.409M |
Gross Profit | 696.312M | 1146.29M | 475.598M | 18.662M | 34.288M |
Reconciled Depreciation | 29.054M | 12.661M | 4.885M | 5.676M | 8.159M |
Ebit | -644.736M | -1699.237M | -421.604M | -120.581M | -182.077M |
Ebitda | -633.767M | -1686.576M | -416.719M | -138.613M | -173.918M |
Depreciation And Amortization | 10.969M | 12.661M | 4.885M | -18.032M | 8.159M |
Operating Income | -644.736M | -1686.576M | -416.719M | -120.581M | -173.918M |
Other Operating Expenses | 2243.687M | 2832.866M | 892.317M | 148.259M | 208.206M |
Interest Expense | 19.88M | 21.127M | 15.145M | 12.188M | 12.188M |
Tax Provision | 4.292M | 29.215M | - | - | - |
Interest Income | - | - | - | 12.1M | 10.938M |
Net Interest Income | -19.88M | -21.127M | -15.145M | -13.612M | -13.612M |
Income Tax Expense | 4.292M | 29.215M | 9.246M | -2.592M | 1.358M |
Total Revenue | 1598.951M | 1146.29M | 475.598M | 18.662M | 34.288M |
Total Operating Expenses | 1341.048M | 2832.866M | 892.317M | 148.259M | 208.206M |
Cost Of Revenue | 902.639M | - | - | 113.842M | 173.797M |
Total Other Income Expense Net | -8.911M | -27.96M | -1.54M | -12.113M | 0.108M |
Net Income From Continuing Ops | -657.939M | -1743.751M | -418.259M | -132.694M | -184.748M |
Net Income Applicable To Common Shares | -657.939M | -1743.751M | -418.259M | -132.694M | -184.748M |
Balance Sheet
(Currency in AUD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Total Assets | 2258.679M | 2576.753M | 1582.479M | 172.957M | 207.978M |
Intangible Assets | - | 4.77M | 5.725M | 5.581M | 6.541M |
Other Current Assets | 1691.429M | 2141.976M | 441.816M | 93.89M | 107.471M |
Total Liab | 2892.757M | 2928.426M | 955.27M | 358.974M | 375.913M |
Total Stockholder Equity | -634.078M | -351.673M | 627.209M | -186.017M | -167.935M |
Other Current Liab | 1521.213M | 709.792M | -327.56M | 19.945M | 1.6M |
Common Stock | 0.868M | 0.764M | 0.714M | 0.324M | 3.849M |
Capital Stock | 0.868M | 0.764M | 0.714M | 0.324M | 3.849M |
Retained Earnings | -4275.889M | -3617.95M | -1874.199M | -1431.801M | -1299.107M |
Good Will | 126.331M | 131.479M | 135.379M | 51.154M | 51.967M |
Other Assets | 28.469M | 16.566M | 5.424M | 1.076M | 1.768M |
Cash | 1336.883M | 1515.116M | 553.398M | 78.823M | 70.154M |
Cash And Equivalents | - | - | - | - | - |
Total Current Liabilities | 2459.944M | 2390.319M | 322.035M | 25.795M | 45.539M |
Current Deferred Revenue | 370.137M | 1422.944M | 273.228M | 1.678M | 10.01M |
Net Debt | -787.102M | -1061.125M | -231.363M | 243.05M | 249.033M |
Short Term Debt | 352.077M | 130.533M | 322.035M | 1.262M | 24.628M |
Short Long Term Debt | 324.881M | - | 322.035M | - | - |
Short Long Term Debt Total | 549.781M | 453.991M | 322.035M | 321.873M | 319.187M |
Other Stockholder Equity | 3647.32M | 3266.866M | 2493.67M | 1257.968M | 1138.323M |
Property Plant Equipment | 400.488M | 228.696M | 179.954M | 11.445M | 28.426M |
Total Current Assets | 1703.391M | 2155.119M | 1248.203M | 97.247M | 119.276M |
Long Term Investments | - | - | - | - | - |
Short Term Investments | - | 0M | 157.649M | 0M | 21.98M |
Net Receivables | 82.375M | 454.993M | 262.012M | 7.5M | -70.323M |
Long Term Debt | 166.466M | 323.458M | 322.035M | 320.611M | 319.187M |
Inventory | 36.683M | -1956.966M | -166.672M | -82.966M | 11.974M |
Accounts Payable | 216.517M | 127.05M | 54.332M | 2.91M | 9.301M |
Accumulated Other Comprehensive Income | -6.377M | -1.353M | 7.024M | -12.508M | -11.191M |
Non Currrent Assets Other | 28.469M | 56.689M | 13.218M | 7.53M | 1.768M |
Non Current Assets Total | 555.288M | 421.634M | 334.276M | 75.71M | 88.702M |
Capital Lease Obligations | 58.434M | 130.533M | 149.727M | 1.262M | - |
Long Term Debt Total | - | 323.458M | 322.035M | 320.611M | 319.187M |
Cash Flow
(Currency in AUD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Investments | -92.985M | 157.64M | -157.64M | 22.016M | 29.968M |
Total Cashflows From Investing Activities | -92.985M | 100.154M | -377.778M | 38.492M | 28.596M |
Total Cash From Financing Activities | 324.988M | 461.713M | 984.762M | 98.384M | 102.805M |
Net Income | -657.939M | -1743.751M | -418.259M | -132.694M | -184.748M |
Change In Cash | -179.414M | 879.521M | 566.558M | 0.221M | -53.472M |
Begin Period Cash Flow | 1528.259M | 648.738M | 82.18M | 81.959M | 135.431M |
End Period Cash Flow | 1348.845M | 1528.259M | 648.738M | 82.18M | 81.959M |
Total Cash From Operating Activities | -415.937M | 322.946M | -42.541M | -136.623M | -184.825M |
Depreciation | 29.054M | 12.661M | 4.885M | 5.676M | 8.159M |
Other Cashflows From Investing Activities | - | - | -165.516M | 18.333M | 18.333M |
Dividends Paid | - | - | - | - | - |
Change To Inventory | -477.801M | -600.326M | -163.161M | -8.872M | - |
Sale Purchase Of Stock | - | 589.62M | 1119.914M | 98.384M | 102.805M |
Other Cashflows From Financing Activities | 169.353M | 24.761M | 205.204M | 0.992M | 2.745M |
Capital Expenditures | 92.985M | 57.486M | 54.622M | 1.857M | 1.372M |
Change In Working Capital | -361.15M | 1733.618M | 12.017M | -24.018M | -21.142M |
Other Non Cash Items | 443.798M | 136.792M | 230.781M | 6.293M | -5.353M |
Free Cash Flow | -508.922M | 265.46M | -97.163M | -138.48M | -186.197M |
Funds
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | SPDR® S&P Biotech ETF | 3 months ago | 8866132 |
2. | Vanguard Total Stock Mkt Idx Inv | 3 months ago | 2845436 |
3. | Vanguard Small Cap Index | 3 months ago | 2311847 |
4. | iShares Russell 2000 ETF | 3 months ago | 2055148 |
5. | Vanguard Institutional Extnd Mkt Idx Tr | 3 months ago | 1353550 |
6. | Vanguard Strategic Equity Inv | 5 months ago | 1332782 |
7. | Vanguard Small Cap Growth Index Inv | 3 months ago | 1295867 |
8. | Direxion Daily S&P Biotech Bull 3X ETF | 3 months ago | 968023 |
9. | Vanguard Explorer Inv | 5 months ago | 867383 |
10. | Fidelity® Small Cap Index | 5 months ago | 815378 |
11. | iShares Biotechnology ETF | 3 months ago | 757676 |
12. | State St Russell Sm/Mid Cp® Indx NL Cl C | 3 months ago | 645425 |
13. | iShares Russell 2000 Growth ETF | 3 months ago | 617317 |
14. | Fidelity® Extended Market Index | 4 months ago | 504125 |
15. | Schwab US Small-Cap ETF™ | 3 months ago | 423696 |
16. | PIMCO RAE US Small Instl | 5 months ago | 395844 |
17. | Vanguard Market Neutral I | 5 months ago | 374308 |
18. | State St Russell Sm Cap® Indx SL Cl I | 3 months ago | 320900 |
19. | Vanguard Health Care ETF | 3 months ago | 307225 |
20. | Vanguard Russell 2000 ETF | 3 months ago | 268049 |
Institutions
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | Vanguard Group Inc | 5 months ago | 11551476 |
2. | State Street Corporation | 5 months ago | 10174617 |
3. | BlackRock Inc | 5 months ago | 7066881 |
4. | Shah Capital Management | 5 months ago | 6330756 |
5. | Millennium Management LLC | 5 months ago | 2556496 |
6. | Morgan Stanley - Brokerage Accounts | 5 months ago | 2275131 |
7. | Geode Capital Management, LLC | 5 months ago | 1860977 |
8. | Citigroup Inc | 5 months ago | 1564953 |
9. | Balyasny Asset Management LLC | 5 months ago | 1380009 |
10. | Bank of America Corp | 5 months ago | 1118539 |
11. | Deep Track Capital, LP | 5 months ago | 1000000 |
12. | Rafferty Asset Management, LLC | 5 months ago | 992470 |
13. | TSP Capital Management Group/LLC | 5 months ago | 966350 |
14. | Northern Trust Corp | 5 months ago | 865783 |
15. | Charles Schwab Investment Management Inc | 5 months ago | 703350 |
16. | Rock Springs Capital Management LP | 5 months ago | 647700 |
17. | BNP Paribas Arbitrage, SA | 5 months ago | 583098 |
18. | Goldman Sachs Group Inc | 5 months ago | 565847 |
19. | Barclays PLC | 5 months ago | 553790 |
20. | Federated Hermes Inc | 5 months ago | 461827 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).